TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$209.3 Million

Icosavax, Inc.

Initial Public Offering

Bookrunner, July 2021

Icosavax, Inc.

Icosavax (the “Company”) is a biotechnology company developing virus-like particle (VLP) vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The Company’s VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, which could induce broad, robust and durable protection against the specific targeted virus. Icosavax’s lead vaccine candidate, IVX-A12, is a bivalent combination of IVX-121, which is designed to target RSV, and IVX-241, which is designed to target hMPV.